Osteopore Limited (ASX: $OSX) has requested the voluntary suspension of its securities from trading starting March 28, 2024. The suspension is due to unexpected delays in completing the 31 December 2023 Annual Report, as the Company's auditors are still compiling necessary information. The voluntary suspension is anticipated to continue until the earlier of the commencement of normal trading on Tuesday, 30 April 2024, or until the 31 December 2023 Annual Report is lodged with the ASX.
The voluntary suspension of Osteopore's securities is a necessary step due to the unforeseen delays in finalizing our Annual Report. We believe it is essential to provide accurate and complete information to our shareholders and the market before resuming trading. We are working diligently to expedite the process and aim to resume normal trading as soon as possible.
Osteopore Limited (ASX: $OSX) has requested a voluntary suspension of its securities from trading due to unexpected delays in completing the 31 December 2023 Annual Report. The Company aims to resume normal trading by April 30, 2024, or upon lodging the Annual Report with the ASX. Osteopore emphasizes the importance of providing accurate and complete information to its shareholders and the market, and assures that efforts are underway to expedite the process and resume trading at the earliest opportunity.